Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC682 in ER+/HER2- Advanced Breast Cancer
NCT05080842Phase 1Terminated
- Sponsor
- Accutar Biotechnology, Inc.
- Start
- Nov 2021
- Primary completion
- Apr 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of AC0682 in breast cancer, sponsored by Accutar Biotechnology, Inc. Primary endpoints: Incidence of Dose Limiting Toxicities and Incidence of Treatment-Emergent Adverse Events. Started Nov 2021; status: terminated.
02
Drugs
AC0682
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05080842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05080842.